At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 936 enrolled
Drug / intervention
MK0217, alendronate sodium/Duration of Intervention: 12 mo +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Randomized, Double-Blind, Double-Dummy, Parallel-Group, Multicenter Study to Evaluate and Compare the Effects of Alendronate and Risedronate on Bone Mineral Density in Postmenopausal Women With Osteoporosis; A 12 Month Extension to: A Randomized, Double-Blind, Double-Dummy, Parallel-Group, Multicenter Study to Evaluate and Compare the Effects of Alendronate and Risedronate on Bone Mineral Density in Postmenopausal Women With Osteoporosis
In Brief
A Phase 3 clinical trial evaluating MK0217, alendronate sodium/Duration of Intervention: 12 mo and Comparator: risedronate / Duration of Intervention: 12 mo for Osteoporosis, Postmenopausal. Completed, enrolled 936 participants.
Detailed Summary
The purpose of this study and 12 month extension is to evaluate the effects of two investigational drugs on osteoporosis in postmenopausal women.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsOsteoporosis, Postmenopausal
Countries--
Collaborators--
Timeline
Phase 3CompletedFinished
2003200420052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartMar 2003
First PostedSep 2004
Primary CompletionOct 2004
Study CompletionSep 2005
TodayJul 2026
First PostedSep 24, 2004
Enrollment StartMar 18, 2003
Primary CompletionOct 18, 2004
Study CompletionSep 28, 2005
TodayJul 2, 2026
Enrollment to primary: 1.6 yearsPosted 21.8 years ago
Interventions
MK0217, alendronate sodium/Duration of Intervention: 12 modrug
Comparator: risedronate / Duration of Intervention: 12 modrug